Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of methods to quantify histone H2AX phosphorylation and its usefulness for prediction of radiosensitivity

  • Borràs Fresneda, Mireia
  • Armengol, Gemma|||0000-0003-2345-1106
  • De Cabo, Martí
  • Barquinero, Joan Francesc|||0000-0003-0084-5268
  • Barrios, Leonardo|||0000-0002-6151-8503
Purpose: The number of radio-induced double-strand breaks is correlated with the number of histone gamma-H2AX (γ-H2AX) foci. For this reason, foci quantification is a useful tool to measure radiation-induced DNA damage and the number of foci has been suggested as a predictive biomarker of radiosensitivity. The aim of the present study was to evaluate the reproducibility of different microscopic methodologies and flow cytometry analysis to score γ-H2AX induction, and its suitability to distinguish a radiosensitive (RS) cell line from a radioresistant (RR) one. Materials and methods: γ-H2AX analyses were performed by semi-automated and automated microscopic methods and by flow cytometry before and after irradiation in two human lymphoblastoid cell lines and in lymphocytes from three healthy donors. Results: Reproducible results were obtained by all the methodologies tested, although not all showed the same sensitivity. The RS cell line always showed higher foci counts and higher levels of immunofluorescence intensity after irradiation than the RR cell line. Conclusions: Our results suggest that microscopic methodologies with z-stage capacity give the most accurate results after 1 Gy irradiation. However, for high doses of ionizing radiation, flow cytometry gives reliable results. Further studies will be necessary to determine the usefulness of γ-H2AX analysis to predict adverse side reactions in radiotherapy patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Is cosmic dust porous?

  • Potapov, Alexey|||0000-0002-3699-7477
  • McCoustra, Martin R. S.|||0000-0002-5716-110X
  • Tazaki, Ryo|||0000-0003-1451-6836
  • Bergin, Edwin A.|||0000-0003-4179-6394
  • Bromley, Stefan|||0000-0002-7037-0475
  • Garrod, Robin T.|||0000-0001-7723-8955
  • Rimola, Albert|||0000-0002-9637-4554
There is a long-standing discussion in the astrophysical/astrochemical community as to the structure and morphology of dust grains in various astrophysical environments (e.g., interstellar clouds, protostellar envelopes, protoplanetary and debris disks, and the atmospheres of exoplanets). Typical grain models assume a compact dust core which becomes covered in a thick ice mantle in cold dense environments. In contrast, less compact cores are likely to exhibit porosity, leading to a pronounced increase in surface area with concomitant much thinner ice films and higher accessibility to the bare grain surface. Several laboratory experimental and theoretical studies have shown that this type of dust structure can have a marked effect on several physico-chemical processes, including adsorption, desorption, mobility, and reactivity of chemical species. Porous grains are thus thought to likely play a particularly important and wide-ranging astrochemical role. Herein, we clarify what is meant by porosity in relation to grains and grain agglomerates, assess the likely astrochemical effects of porosity and ask whether a fractal/porous structural/morphological description of dust grains is appropriate from an astronomical perspective. We provide evidence for high porosity from laboratory experiments and computational simulations of grains and their growth in various astrophysical environments, and assess the observational constraints and perspectives on cosmic dust porosity. Overall, our paper discusses the effects of including porosity in dust models and the need to use such models for future astrophysical, astrochemical and astrobiological studies involving surface or solid-state processes.
Repisalud
Publication Artículo científico (JournalArticle)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

  • Quintela Fandino, Miguel Angel
  • Apala, Juan V
  • Malon, Diego
  • Mouron, Silvana Andrea
  • Hornedo, Javier
  • Gonzalez-Cortijo, Lucia
  • Colomer, Ramon
  • Guerra, Juan
BACKGROUND: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvant setting, with the goal of obtaining pharmacodynamic proof of the effects of combined aromatase and FGFR1 inhibition and to establish the RP2D for nintedanib combined with letrozole. PATIENTS AND METHODS: Women with early-stage luminal breast cancer were eligible for enrollment in the study. Dose level 1 was nintedanib (150 mg/bid) plus letrozole (2.5 mg/day) administered for a single 28-day cycle (DLT assessment period), followed by a classic 3 + 3 schedule. FGF23 and 17-B-estradiol levels were determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28. Patients were allowed to continue treatment for 6 cycles. The primary study endpoint was a demonstration of FGFR1 modulation (defined as a 25% increase in the plasma FGF23 level). RESULTS: A total of 19 patients were enrolled in the study (10 in the expansion cohort following dose escalation). At the RP2D (nintedanib 200 mg/bid plus letrozole 2.5 mg/day), we observed a 55% mean increase in the plasma FGF23 level, and 81.2% of the patients had no detectable level of 17-B-estradiol in their plasma (87.5% of the patients treated with letrozole alone). Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and twofold increases in their respective plasma concentrations. Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period. CONCLUSION: Combined treatment with nintedanib (200 mg/bid) plus letrozole (2.5 mg/day) effectively suppressed FGFR1 and aromatase activity, and these respective doses can be used as starting doses in any subsequent trials. However, drug-drug interactions may produce tolerability issues when these drugs are co-administered for an extended time period (e.g., 6 months). Patients enrolled in future trials with these drugs should be carefully monitored for their FGF23 levels and signs of toxicity, and those findings should guide individualized treatment decisions. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov under reg. # NCT02619162, on December 2, 2015.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

  • Reventós-Presmanes, Jana
  • Cano-Cabañero, Andrea
  • Hernández-Romero, Ismael
  • Lundback, David
  • Martínez, Marta
  • Moler, Ruben
  • Milagro, Javier
  • Pellicer-Sendra, Berta
  • Regany-Closa, Mariona
  • Ros Ruiz, Santiago
  • Fambuena-Santos, Carlos
  • Correas-García, María
  • Herrero-Martín, Clara|||0000-0001-5053-296X
  • Llorente-Lipe, Inés|||0009-0005-3386-0407
  • Moreno-López, Raúl
  • Andreu M. Climent|||0000-0002-7260-8811
[EN] Rapid, safe, and effective cardiac mapping is critical for the management of complex arrhythmias, yet current methods face significant limitations. The 12-lead electrocardiogram (ECG), while essential for initial diagnosis, lacks the spatial resolution and depth needed to guide advanced procedures such as catheter ablation or cardiac resynchronization therapy device implantation. On the other hand, invasive mapping techniques provide detailed electrical activity but require multiple catheter placements, increasing procedural risks and complexity. These methods are time-consuming, expensive, and offer limited real-time assessment, especially in dynamic arrhythmias like atrial fibrillation (AF), unstable arrhythmia, and cardiac resynchronization therapy (CRT). This study introduces a noninvasive, imageless electrocardiographic imaging (Imageless-ECGI) system designed to complement traditional methods by providing real-time, beat-to-beat cardiac maps. Without the need for pre-procedural imaging, this system captures high-resolution electrical activity across the entire heart, offering a safer and more efficient alternative to invasive mapping. By combining the immediacy of surface recordings with the spatial accuracy of modern computational models, the Imageless-ECGI system bridges the gap between traditional ECG and invasive mapping, potentially transforming the workflow in electrophysiology labs., also acknowledge support from the CERCA Programme/Generalitat de Catalunya. MPL funded (2023-2025) through a Rio Hortega contract CM22/00107 [Instituto de Salud Carlos III (ISCIII) ; Fondo Social Europeo (FSE) ] . The authors thank Neus Portella and Sheila Marco for providing secretarial support, and to the medical and nursing teams for their clinical support at Hospital Clinic de Barcelona, Hospital General Universitario Gregorio Maranon, Hospital Universitari i Politecnic La Fe. They also extend they're thanks to Almudena Albertos from Corify Care SL, Madrid, Spain and Arantxa Carrasco from Universitat Politecnica de Valencia.r also acknowledge support from the CERCA Programme/Generalitat de Catalunya. MPL funded (2023-2025) through a Rio Hortega contract CM22/00107 [Instituto de Salud Carlos III (ISCIII) ; Fondo Social Europeo (FSE) ] . The authors thank Neus Portella and Sheila Marco for providing secretarial support, and to the medical and nursing teams for their clinical support at Hospital Clinic de Barcelona, Hospital General Universitario Gregorio Maranon, Hospital Universitari i Politecnic La Fe. They also extend they're thanks to Almudena Albertos from Corify Care SL, Madrid, Spain and Arantxa Carrasco from Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Optimized single-point left ventricular pacing leads to improved resynchronization compared with multipoint pacing

  • San Antonio, Rodolfo
  • Guasch, Eduard
  • González-Ascaso, Ana
  • Jiménez-Arjona, Rafael
  • Pujol-López, Margarida
  • Doltra, Adelina
  • Alarcón, Francisco
  • Garre, Paz
  • Liberos Mascarell, Alejandro
  • Trotta, Omar
  • Quinto, Levio
  • Borras, Roger
  • Arbelo, Elena
  • Roca-Luque, Ivo
  • Atienza, Felipe
  • Brugada, Josep
  • Fernandez-Aviles, Francisco
  • Sitges, Marta
  • Tolosana, José María
  • Mont, Lluis
  • Andreu M. Climent|||0000-0002-7260-8811
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Background Multipoint pacing (MPP) in cardiac resynchronization therapy (CRT) activates the left ventricle from two locations, thereby shortening the QRS duration and enabling better resynchronization; however, compared with conventional CRT, MPP reduces battery longevity. On the other hand, electrocardiogram-based optimization using the fusion-optimized intervals (FOI) method achieves more significant reverse remodeling than nominal CRT programming. Our study aimed to determine whether MPP could attain better resynchronization than single-point pacing (SPP) optimized by FOI. Methods This prospective study included 32 consecutive patients who successfully received CRT devices with MPP capabilities. After implantation, the QRS duration was measured during intrinsic rhythm and with three pacing configurations: MPP, SPP-FOI, and MPP-FOI. In 14 patients, biventricular activation times (by electrocardiographic imaging, ECGI) were obtained during intrinsic rhythm and for each pacing configuration to validate the findings. Device battery longevity was estimated at the 45-day follow-up. Results The SPP-FOI method achieved greater QRS shortening than MPP (-56 +/- 16 vs. -42 +/- 17 ms, p < .001). Adding MPP to the best FOI programming did not result in further shortening (MPP-FOI: -58 +/- 14 ms, p = .69). Although biventricular activation times did not differ significantly among the three pacing configurations, only the two FOI configurations achieved significant shortening compared with intrinsic rhythm. The estimated battery longevity was longer with SPP than with MPP (8.1 +/- 2.3 vs. 6.3 +/- 2.0 years, p = .03). Conclusions SPP optimized by FOI resulted in better resynchronization and longer battery duration than MPP., Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares, Grant/Award Number: CB16/11/00354; Instituto de Salud Carlos III, Grant/Award Numbers: DTS16/0160, PI16/00435, PI16/00703, PI17/01059, PI17/01106; Sociedad Espanola de Cardiologia, Grant/Award Numbers: 2018, SEC_ESTIM_01; Agencia deGestio d'Ajuts Universitaris i de Recerca, Grant/AwardNumber: 2017_SGR_1548; Fundacio laMarato de TV3, Grant/Award Number: 20152730; Horizon 2020 Framework Programme, Grant/Award Number: 633196 - CATCH MEproject; European Regional Development Fund, Grant/Award Number: EITHealth 19600 AFFINE
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Noninvasive assessment of the ventricular arrhythmogenic substrate using electrocardiographic imaging during sinus rhythm: The NIAVAS study

  • Reventós-Presmanes, Jana
  • Hernández-Romero, Ismael
  • Pecllier-Sendra, B.
  • Guillen-Buisan, E.
  • Serrano-Campaner, J.
  • Invers-Rubio, E.
  • Regany-Closa, M.
  • Garre, Paz
  • Borras, Roger
  • Costafreda, Adriana
  • Arbelo, Elena
  • Tolosana, Jose M.
  • Guasch, E.
  • Althoff, Till F.
  • Guichard, Jean-Baptiste
  • Falzone, Pasquale V.
  • Vázquez-Calvo, Sara
  • Elivhots Ayauja
  • Porta-Sanchez, Andreu
  • Roca-Luque, Ivo
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
  • Andreu M. Climent|||0000-0002-7260-8811
[EN] Background Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) identifies structural properties associated with ventricular tachycardia (VT) but lacks functional information. Noninvasive identification of slow conduction regions using electrocardiographic imaging (ECGI) could complement LGE-CMR to aid VT risk stratification. Objective This study aimed to evaluate the relationship between ventricular arrhythmogenic substrate and regional ECGI markers during sinus rhythm in patients with ischemic cardiomyopathy (ICM). Methods Seventy-two patients were included: 29 with ICM evidenced by LGE-CMR referred for VT ablation, 17 with ICM with implantable cardioverter-defibrillator for primary prevention without documented VT, and 26 controls. ECGI-derived regional activation dispersion (rAD) and pseudo-regional conduction velocity (pseudo-rCV) were analyzed and compared between scarred and healthy regions based on LGE, and between patients with ICM with and without previous VT. In a subgroup with electroanatomic mapping (n = 16), deceleration zones were correlated with ECGI. Results Scarred regions showed higher rAD (46.3 ± 2.2 vs 30.1 ± 1.7 ms, P < .001) and reduced pseudo-rCV (149.9 ± 3.0 vs 165.7 ± 2.4 cm/s, P < .001) than healthy regions. In the subgroup with sinus rhythm electroanatomic mapping, regions containing deceleration zones showed increased rAD (64.9 ± 5.4 vs 43.1 ± 3.1 ms, P < .001), and ECGI identified 70.4% of those zones. At the patient level, the mean of the 3 regions with the highest activation dispersion differentiated patients with ICM with and without previous VT (rAD ¿60.0 ms, sensitivity 75.9%, area under the curve [AUC] 0.75, P = .005) and identified patients with ICM from controls (rAD ¿39.5 ms, AUC 0.93). Conclusion This study introduces a novel regional ECGI methodology demonstrating that rAD identifies abnormalities linked to arrhythmogenic substrate and could help identify patients at risk of VT. These findings highlight ECGI¿s potential as a complementary tool to LGE-CMR., This research was funded by the European Institute of Innovation and Technology (EIT Health) under grant agreement no. 230129. In addition, the research was supported by Ministerio de Ciencia, Innovación y Universidades MCIN/AEI/10.13039/501100011033 (grant PID2023-149812OB-I00), European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (CNS2022-135512, PTQ2023-013018, and CPP2021- 008562), and Fondo Europeo de Desarrollo Regional European Union (CPP2023-010504). Additional support came from Generalitat Valenciana and European Social Fund Investing in Your Future (grants CIAPOS/2021/238 and CIAICO/2022/020), Instituto de Salud Carlos III (grant CIBERCV16 CB16/11/00354), and Catalonia, Spain (grants 2021_SGR_01350 and SGR21/GENCAT).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Substrate Mapping for Ventricular Tachycardia Ablation Through High-Density Whole-Chamber Double Extra Stimuli The S3 Protocol

  • Guichard, Jean Baptiste
  • Regany-Closa, Mariona
  • Vázquez-Calvo, Sara
  • Zazu, Blanca
  • Pellicer Sendra, Berta
  • Serrano-Campaner, Jaume
  • Molero-Pereira, Silvia
  • Borras, Roger
  • Ortiz, Jose Tomas
  • Falzone, Pasquale Valerio
  • Eulogio, Frida
  • Reventós-Presmanes, Jana
  • Garre, Paz
  • Arbelo, Elena
  • Althoff, Till Friedrisch
  • Eduard Guasch
[EN] Background: A partial delineation of targets for ablation of ventricular tachycardia (VT) during a stable rhythm is likely responsible for a suboptimal success rate. The abnormal low-voltage near-field functional components may be hidden within the high-amplitude far-field signal. Objectives: The aim of this study was to evaluate the benefit and feasibility of functional substrate mapping using a full-ventricle S3 protocol and to assess its colocalization with arrhythmogenic conducting channels (CCs) on late gadolinium enhancement cardiac magnetic resonance. Methods: An S3 mapping protocol with a drive train of S1 followed by S2 (effective refractory period + 30 ms) and S3 (effective refractory period + 50 ms) from the right ventricular apex was performed in 40 consecutive patients undergoing scar-related VT ablation. Deceleration zones (DZs) and areas of late potentials (LPs) were identified for all maps. A preprocedural noninvasive substrate assessment was done using late gadolinium enhancement cardiac magnetic resonance and postprocessing with automated CC identification. Results: The S3 protocol was completed in 34 of the 40 procedures (85.0%). The S3 protocol enhanced the identification of VT isthmus on the basis of DZ (89% vs 62%; P < 0.01) and LP (93% vs 78%; P = 0.04) assessment. The percentage of CCs unmasked by DZs and LPs using S3 maps was significantly higher than the ones using S2 and S1 maps (78%, 65%, and 48% [P < 0.001] and 88%, 81%, and 68% [P < 0.01], respectively). The functional substrate identified during S3 activation mapping was significantly more extensive than the one identified using S2 and S1, including a greater number of DZs (2.94, 2.47, and 1.82, respectively; P < 0.001) and a wider area of LPs (44.1, 38.2, and 29.4 cm(2), respectively; P < 0.001). After VT ablation, 77.9% of patients have been VT free during a median follow-up period of 13.6 months. Conclusions: The S3 protocol was feasible in 85% of patients, allows a better identification of targets for ablation, and might improve VT ablation results., Dr Guichard has received institutional grant support from the French Federation of Cardiology and from "Contractes d'Investigacio Avan-cada Fundacio BBVA-Hospital Clinic Barcelona Joan Rodes - Josep Baselga 2022" (HCB_BIO_001/2) . This study was supported in part by grant PI20/00693, FEDER (European Commission) /CB16/11/00354, Instituto de Salud Carlos III, and grant 2021_SGR_01350, SGR21/GEN-CAT.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Large scale phenotyping and molecular analysis in a germplasm collection of rocket salad (Eruca vesicaria) reveal a differentiation of the gene pool by geographical origin

  • Guijarro-Real, Carla
  • Navarro, Alejandra
  • Esposito, Salvatore
  • Festa, Giovanna
  • Macellaro, Rosaria
  • Di Cesare, Carlo
  • Cardi, Teodoro
  • Tripodi, Pasquale
  • Fita, Ana|||0000-0002-8637-5852
  • Rodríguez Burruezo, Adrián|||0000-0002-4530-8071
  • Prohens Tomás, Jaime|||0000-0003-1181-9065
[EN] Cultivated rocket (Eruca vesicaria) is a leafy vegetable highly appreciated for its healthpromoting virtues and consumed both raw and cooked as ready-to-use vegetable. Despite Eruca being cultivated worldwide, only a few cultivars are available and limited breeding activities have been carried out so far. Therefore, the genetic resources available represent an unexploited potential source of variation for breeding. In the present study, 155 E. vesicaria accessions from 30 countries across Europe, Asia, Africa, and America have been characterized for 54 qualitative and quantitative morphological and quality traits. Conventional descriptors and automated tools for the determination of the quality, morphology, and colour of leaves have been used. Genetic diversity was assessed using 15 inter simple sequence repeat and simple sequence repeat markers. A high level of diversity was evidenced in the collection. Significant differences were found in most of the traits with the exception of five pseudo-qualitative descriptors. The first and second dimensions of the principal components analysis with phenotypic traits accounted for 25.69% of total variation showing a stratification of the genotypes according to the European and Asian origins. In total, 75% of the variation was contained in the first 15 components having eigenvalues higher than 1.0. Also, the population structure divided the collection into two main clusters separating European genotypes from the rest. Furthermore, hierarchical cluster analysis confirmed a geographical separation, grouping the accessions into three major clusters, which were differentiated by plant architecture, leaf and flower colour, leaf water status, leaf blade shape and hairiness of the leaves and stem. Our approach has broadened the knowledge of the diversity within the Eruca gene pool, thus contributing to identify sources of variation and to select the best candidates for cultivated rocket breeding programs, as well as to determine the genetic basis of plant and leaf traits in future genome-wide association studies., The work was supported by 'RGV-FAO' project funded by the Italian Ministry of Agriculture, Food and Forestry. C. Guijarro-Real thanks the Ministerio de Educacion, Cultura y Deporte of Spain (MECD) for its financial support by means of a predoctoral FPU Grant (FPU14/06798), and for the specific grant for mobility (EST17/00354) from the same Organization.
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Evidence of a warp-weighted loom in the Bronze Age settlement of Cabezo Redondo (south-east Spain)

  • Basso Rial, Ricardo E.
  • García Atiénzar, Gabriel
  • Carrión Marco, Yolanda
  • Martín de la Sierra Pareja, Paula
  • Barciela, Virginia
  • Hernández Pérez, Mauro S.
  • García Atiénzar, Gabriel|||/items/eb9fcbf2-0f0c-43ef-a59f-082f0bfee273
  • Barciela, Virginia|||/items/a6473df9-b628-4f41-8ac2-a48ebee81403
The deep history of weaving is attested by spindle whorls and loom weights, so the evolution of techniques may be tracked through changes in these durable artefacts; however, wooden looms rarely preserve. Here, the authors document a series of loom weights and associated charred timbers and fibres that represent the remains of a Bronze Age warp-weighted loom, uncovered at the settlement of Cabezo Redondo in south-eastern Spain. Based on the number, weight and size of the weights, hypothetical reconstructions of loom setup and resultant textile products are proposed, revealing possible diversification of weaving processes in the mid-second millennium BC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke

  • Simats, Alba
  • Ramiro Pascual, Laura
  • Valls, Raquel
  • Ramón, Helena de
  • García-Rodríguez, Paula
  • Orset, Cyrille
  • Artigas, Laura
  • Sardon, Teresa
  • Rosell, Anna
  • Montaner, Joan
Ischemic stroke is a primary cause of morbidity and mortality worldwide. Beyond the approved thrombolytic therapies, there is no effective treatment to mitigate its progression. Drug repositioning combinational therapies are becoming promising approaches to identify new uses of existing drugs to synergically target multiple disease-response mechanisms underlying complex pathologies. Here, we used a systems biology-based approach based on artificial intelligence and pattern recognition tools to generate in silico mathematical models mimicking the ischemic stroke pathology. Combinational treatments were acquired by screening these models with more than 5 million two-by-two combinations of drugs. A drug combination (CA) formed by ceruletide and alpha-1 antitrypsin showing a predicted value of neuroprotection of 92% was evaluated for their synergic neuroprotective effects in a mouse pre-clinical stroke model. The administration of both drugs in combination was safe and effective in reducing by 39.42% the infarct volume 24 h after cerebral ischemia. This neuroprotection was not observed when drugs were given individually. Importantly, potential incompatibilities of the drug combination with tPA thrombolysis were discarded in vitro and in vivo by using a mouse thromboembolic stroke model with t-PA-induced reperfusion, revealing an improvement in the forepaw strength 72 h after stroke in CA-treated mice. Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke. In conclusion, we have identified a promising combinational treatment with neuroprotective effects for the treatment of ischemic stroke., Neurovascular Research Laboratory acknowledges funding for this project by PI15/00354 and PI18/00804 grants from Instituto Carlos III; the Spanish neurovascular research network INVICTUS PLUS (RD16/0019/0021) also from the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER); the program 2017-SGR-1427 from the Generalitat de Catalunya; and the “Advanced Neuroprotection Repurposing Drugs and Nutraceuticals for Stroke in Andalusia: NARDNIA Project,” and COMBINA2 project both funded by the Andalusian Ministry of Health (PE-0527–2019 and PY20-01351). L.R. is supported by a predoctoral fellowship grant (IFI17/00012), from Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Knockdown of T-cell intracellular antigens triggers cell proliferation, invasion and tumour growth

  • Reyes, Raquel
  • Alcalde, José
  • Carrascoso, Isabel
  • Reyes, Raquel
  • Ludeña, María Dolores
TIA (T-cell intracellular antigen) proteins function as DNA/RNA trans-acting regulators to expand transcriptome and proteome diversity in mammals. In the present paper we report that the stable silencing of TIA1 and/or TIAR/TIAL1 (TIA1-related/like protein 1) expression in HeLa cells enhances cell proliferation, anchorage-dependent and -independent growth and invasion. HeLa cells lacking TIA1 and/or TIAR generate larger and faster-growing epithelial tumours with high rates of proliferation and angiogenesis in nude mice xenografts. Protein array analysis of a collection of human tumours shows that TIA1 and TIAR protein expression is down-regulated in a subset of epithelial tumours relative to normal tissues. Our results suggest a link between the epigenetic control exerted by TIA proteins and the transcriptional and post-transcriptional regulation of a subset of specific genes involved in tumour progression. Taken together, these results are consistent with a role for TIA proteins as growth/tumour-suppressor genes., This work was supported by the Fondo de Investigaciones Sanitarias-FEDER [grant number PI051605]; the Ministerio de Ciencia e Innovación-FEDER [grant number BFU2008–00354]; and the Agencia Estatal Consejo Superior de Investigaciones Científicas [grant number 200920I108]. The Centro de Biología Molecular ‘Severo Ochoa’ receives an institutional grant from the Fundación Ramón Areces, Spain., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

  • Quintela-Fandino, Miguel
  • Holgado, Esther
  • Manso, Luis
  • Cortés Castan, Javier
  • Morales, Serafin
  • Bermejo, Begoña
  • Colomer, Ramon
Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu, Bevacizumab; Durvalumab; Cáncer de mama HER2 negativo, Bevacizumab; Durvalumab; HER2-negative breast cancer, Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Methods Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as “non-progressors” if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Results Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors’ tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased TREG signatures in gene expression studies in baseline—post-bevacizumab—tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating TREGs in non-progressors. Conclusions This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing TREGs cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting., MQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM) - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. SM is a recipient of the following grants: Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2017-83732-R; AEI/FEDER, EU) and co-funded by Comunidad de Madrid (B2017/BMD3733; Immunothercan-CM). RC is a recipient RC is a recipient of the ISCIII grants PIE15/00068 and PI17/01865. The study was also funded by CRIS Contra el Cancer Foundation and Astra Zeneca Spain. Astra Zeneca Spain provided durvalumab.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management

  • Ramiro, Laura|||0000-0002-4121-4609
  • Simats Oriol, Alba|||0000-0002-0415-1135
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Montaner, Joan|||0000-0003-4845-2279
Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since the only approved therapies are directed toward restoring blood flow to the affected brain area. However, due to the reduced time window during which these therapies are effective, few patients benefit from them; therefore, alternative treatments are urgently needed to reduce stroke brain damage in order to improve patients' outcome. The inflammatory response triggered after the ischemic event plays an important role in the progression of stroke; consequently, the study of inflammatory molecules in the acute phase of stroke has attracted increasing interest in recent decades. Here, we provide an overview of the inflammatory processes occurring during ischemic stroke, as well as the potential for these inflammatory molecules to become stroke biomarkers and the possibility that these candidates will become interesting neuroprotective therapeutic targets to be blocked or stimulated in order to modulate inflammation after stroke.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer, a pilot clinical trial

  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Holgado, Esther
  • Manso, Luis|||0000-0002-1683-550X
  • Morales, Serafin|||0000-0001-7445-4193
  • Bermejo, Begoña
  • Colomer, Ramon|||0000-0002-6393-3444
  • Apala, Juan V.
  • Blanco, Raquel
  • Muñoz, Manuel
  • Caleiras, Eduardo
  • Iranzo, Vega
  • Martínez López, Mario
  • Dominguez, Orlando
  • Hornedo, Javier
  • Gonzalez-Cortijo, Lucia
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Gasol Cudos, Ariadna
  • Malon, Diego
  • Lopez-Alonso, Antonio
  • Moreno-Ortíz, María C.
  • Mouron, Silvana
  • Mañes, Santos
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as "non-progressors" if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors' tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased T signatures in gene expression studies in baseline-post-bevacizumab-tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating T in non-progressors. This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing T cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting. (www.clinicaltrials.gov):. Registered on June 16, 2020.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

  • Simats Oriol, Alba|||0000-0002-0415-1135
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Ramiro, Laura|||0000-0002-4121-4609
  • Giralt, Dolors
  • Gill, Natalia
  • Penalba, Anna
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Montaner, Joan|||0000-0003-4845-2279
The limited accessibility to the brain has turned the cerebrospinal fluid (CSF) into a valuable source that may contribute to the complete understanding of the stroke pathophysiology. Here we have described the CSF proteome in the hyper-acute phase of cerebral ischemia by performing an aptamer-based proteomic assay (SOMAscan) in CSF samples collected before and 30 min after male Wistar rats had undergone a 90 min Middle Cerebral Artery Occlusion (MCAO) or sham-surgery. Proteomic results indicated that cerebral ischemia acutely increased the CSF levels of 716 proteins, mostly overrepresented in leukocyte chemotaxis and neuronal death processes. Seven promising candidates were further evaluated in rat plasma and brain (CKB, CaMK2A, CaMK2B, CaMK2D, PDXP, AREG, CMPK). The 3 CaMK2 family-members and CMPK early decreased in the infarcted brain area and, together with AREG, co-localized with neurons. Conversely, CKB levels remained consistent after the insult and specifically matched with astrocytes. Further exploration of these candidates in human plasma revealed the potential of CKB and CMPK to diagnose stroke, while CaMK2B and CMPK resulted feasible biomarkers of functional stroke outcome. Our findings provided insights into the CSF proteome following cerebral ischemia and identified new outstanding proteins that might be further considered as potential biomarkers of stroke.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Emergent Spin Frustration in Neutral Mixed-Valence 2D Conjugated Polymers, A Potential Quantum Materials Platform

  • Alcón, Isaac|||0000-0002-7569-2000
  • Ribas-Ariño, Jordi|||0000-0003-4088-6187
  • Moreira, Ibério de P.R.|||0000-0002-2684-6982
  • Bromley, Stefan|||0000-0002-7037-0475
Two-dimensional conjugated polymers (2DCPs)-organic 2D materials composed of arrays of carbon sp 2 centers connected by π-conjugated linkers-are attracting increasing attention due to their potential applications in device technologies. This interest stems from the ability of 2DCPs to host a range of correlated electronic and magnetic states (e.g., Mott insulators). Substitution of all carbon sp 2 centers in 2DCPs by nitrogen or boron results in diamagnetic insulating states. Partial substitution of C sp 2 centers by B or N atoms has not yet been considered for extended 2DCPs but has been extensively studied in the analogous neutral mixed-valence molecular systems. Here, we employ accurate first-principles calculations to predict the electronic and magnetic properties of a new class of hexagonally connected neutral mixed-valence 2DCPs in which every other C sp 2 nodal center is substituted by either a N or B atom. We show that these neutral mixed-valence 2DCPs significantly energetically favor a state with emergent superexchange-mediated antiferromagnetic (AFM) interactions between C-based spin- 1 / centers on a triangular sublattice. These AFM interactions are surprisingly strong and comparable to those in the parent compounds of cuprate superconductors. The rigid and covalently linked symmetric triangular AFM lattice in these materials thus provides a highly promising and robust basis for 2D spin frustration. As such, extended mixed-valence 2DCPs are a highly attractive platform for the future bottom-up realization of a new class of all-organic quantum materials, which could host exotic correlated electronic states (e.g., unusual magnetic ordering, quantum spin liquids).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Profile of Adult Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia Patients According to Pneumococcal Vaccination Status

  • Morales-Suárez-Varela, María|||0000-0003-0785-1492
  • Toledo, Diana|||0000-0003-0794-9238
  • Fernández-Sierra, María Amelia
  • Liébana, María
  • Rubiera, Gerardo
  • Navarro Rubio, Gemma|||0000-0002-7195-9046
  • Prados, Concepción
  • Chamarro, Judith
  • Peraita-Costa, Isabel
  • Domínguez, Ángela|||0000-0003-0219-1907
Certain patient profile characteristics, such as preexisting medical conditions, can modify the risk of developing SARS-CoV-2 pneumonia among adults vaccinated and not vaccinated against pneumococcal disease. This retrospective cohort study aimed to quantify the risk of pneumonia caused by SARS-CoV-2 among individuals from 15 to 64 years old with and without pneumococcal vaccination in Spain during the 2020-2021 influenza season and establish a risk profile of patients more likely to develop SARS-CoV-2 pneumonia. Data (demographic information, patient medical history, and lifestyle habits) were gathered both directly from the patient via personal interview and by reviewing electronic medical records. In an adjusted analysis for pneumococcal vaccinated patients, visits to hospital outpatient clinics were protective while visits to primary health care services, being widowed, obese, and not using masks in outdoor open spaces were identified as risk factors. For patients who had not received a pneumococcal vaccine, visits to hospital outpatient clinics were protective, while being overweight or obese, alcohol consumption, and not using masks in outdoor open spaces were identified as risk factors. Concerning comorbidities, in the pneumococcal vaccinated group none were found to be protective but having diabetes or other respiratory diseases were identified as risk factors. In the unvaccinated group, undergoing immunosuppressive treatment and having metastatic tumors were protective factors, while cerebrovascular disease and obesity with a BMI ≥ 40 were risk factors. A similar risk profile for developing SARS-CoV-2 pneumonia in pneumococcal vaccinated and non-vaccinated individuals was found. Generally, vaccinated individuals had a lower risk of developing SARS-CoV-2. The findings suggest that vaccination against S. pneumoniae could prevent and reduce SARS-CoV-2 pneumonia. Additionally, this study has identified individuals with other medical conditions, such as obesity, underweight, diabetes, and a history of respiratory diseases, who are at an increased risk of developing SARS-CoV-2 pneumonia and could benefit from vaccination and supervision.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

  • Quintela-Fandino, Miguel
  • Holgado, Esther
  • Manso, Luis
  • Cortés Castan, Javier
  • Morales, Serafin
  • Bermejo, Begoña
  • Colomer, Ramon
Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu, Bevacizumab; Durvalumab; Cáncer de mama HER2 negativo, Bevacizumab; Durvalumab; HER2-negative breast cancer, Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Methods Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as “non-progressors” if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Results Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors’ tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased TREG signatures in gene expression studies in baseline—post-bevacizumab—tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating TREGs in non-progressors. Conclusions This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing TREGs cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting., MQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM) - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. SM is a recipient of the following grants: Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2017-83732-R; AEI/FEDER, EU) and co-funded by Comunidad de Madrid (B2017/BMD3733; Immunothercan-CM). RC is a recipient RC is a recipient of the ISCIII grants PIE15/00068 and PI17/01865. The study was also funded by CRIS Contra el Cancer Foundation and Astra Zeneca Spain. Astra Zeneca Spain provided durvalumab.